Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-o...
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
About this item
Full title
Author / Creator
Seidel, Ursula Jördis Eva , Schlegel, Patrick , Grosse-Hovest, Ludger , Hofmann, Martin , Aulwurm, Steffen , Pyz, Elwira , Schuster, Friedhelm R , Meisel, Roland , Ebinger, Martin , Feuchtinger, Tobias , Teltschik, Heiko-Manuel , Witte, Kai-Erik , Schwarze, Carl-Philipp , Rammensee, Hans-Georg , Handgretinger, Rupert , Jung, Gundram and Lang, Peter
Publisher
United States: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Prognosis of primary refractory and relapsed pediatric B-lineage acute lymphoblastic leukemia (ALL) is very poor. Relapse rates significantly correlate with persistent minimal residual disease (MRD). In MRD, favorable effector-target ratios prevail and thus this situation might be optimally suited for immunotherapy with antibodies recruiting immuno...
Alternative Titles
Full title
Reduction of Minimal Residual Disease in Pediatric B-lineage Acute Lymphoblastic Leukemia by an Fc-optimized CD19 Antibody
Authors, Artists and Contributors
Author / Creator
Schlegel, Patrick
Grosse-Hovest, Ludger
Hofmann, Martin
Aulwurm, Steffen
Pyz, Elwira
Schuster, Friedhelm R
Meisel, Roland
Ebinger, Martin
Feuchtinger, Tobias
Teltschik, Heiko-Manuel
Witte, Kai-Erik
Schwarze, Carl-Philipp
Rammensee, Hans-Georg
Handgretinger, Rupert
Jung, Gundram
Lang, Peter
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5113107
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5113107
Other Identifiers
ISSN
1525-0016
E-ISSN
1525-0024
DOI
10.1038/mt.2016.141
